(P032) Clinical Outcomes for Hybrid Forward and Inverse Planned IMRT for Supine Craniospinal Irradiation

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Conventional matching techniques of craniospinal irradiation (CSI) require patients to be in the prone position in order to use skin surface markers to align matched or gapped adjacent fields. Because of safety concerns regarding field overlap with a blind match, there has been reluctance to treat patients supine. Here, we present the clinical outcomes of patients treated with our supine CSI technique using a gradient match of brain and spinal fields.

Stephanie K. Childs, MD, Jon J. Kruse, PhD, Kevin L. Kisrow, CMD, RTT, Nadia N. Laack, MD; Mayo Clinic

Background: Conventional matching techniques of craniospinal irradiation (CSI) require patients to be in the prone position in order to use skin surface markers to align matched or gapped adjacent fields. Small setup misalignments of even 1 mm can lead to large deviations in delivered dose of up to 40%. In addition, the prone position is cumbersome for patient positioning, especially for pediatric patients requiring anesthesia for treatment. Because of safety concerns regarding field overlap with a blind match, there has been reluctance to treat patients supine. Here, we present the clinical outcomes of patients treated with our supine CSI technique using a gradient match of brain and spinal fields.

Methods: We retrospectively reviewed the charts of all patients who received CSI at Mayo Clinic from 2009–2013. All patients were simulated in the supine position, and all radiotherapy plans were created using a hybrid of forward and inverse planned intensity-modulated radiation therapy (IMRT). The inferior borders of the brain fields and superior border of the lower spine field are designed with long, gradual dose gradients created by sequential closing of the 5-mm multileaf collimator (MLC) leaves using forward planned, multiple static segment IMRT delivery. Next, a sliding window upper spine IMRT field is created by the inverse planning system to match the gradients of the brain and lower spine fields. Daily patient localization is confirmed by kV On-Board imaging of the cranial fields and a single posterior spine image. Subsequent shifts are calculated based on couch coordinates and planned isocenter shifts, not skin markings. To verify the robustness and safety of the CSI plans, dose was calculated, assuming a systematic setup error of 3 mm. Resulting dose deviations were +/− 15%.

Results: We identified 26 patients with a median age of 16 years (range: 3.4–65.5 y). Thirteen patients had medulloblastoma, nine had primitive neuroectodermal tumors (PNETs), two had pure germinomas, one had a mixed germ cell tumor, and one had an anaplastic glioneuronal tumor. The median dose delivered to the neuraxis was 36 Gy (range: 18–39.6 Gy), and the median boost dose to the tumor bed, posterior fossa, or ventricles was 55.8 Gy (range: 30.6–60 Gy). At a median follow-up of 2.8 years (range: 0.2–4.7 y), no patient had an isolated spinal recurrence and no patient had a clinically or radiographically apparent spinal myelopathy. One patient with medulloblastoma who presented with diffuse leptomeningeal disease and one patient with a supratentorial PNET recurred with diffuse leptomeningeal disease throughout the neuraxis. Seven of the nine patients with PNETs had an intracranial recurrence, five of which were in the primary tumor bed.

Conclusions: We saw no clinical evidence of isolated spinal recurrences or myelopathies at the field gradients using our hybrid forward and inverse planned IMRT supine CSI technique. Smooth field transitions obviate the need for match line shifts, allowing patients to be treated more comfortably in the supine position. In addition, the hybrid IMRT plans are less susceptible to geometric inaccuracies and the resulting dose deviations.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content